InhibeX is targeting disease states which may be induced by a new mechanism of extra-cellular receptor cleavage. The InhibeX technology is based on a UC San Diego innovation entitled “Blockade of Inflammation in Hypertension and Metabolic Syndrome” and covers the following fields of use:

  • Hypertension
  • Insulin resistance (Type II diabetes)
  • Syndrome X
  • Metabolic disease
  • Thrombosis
  • Receptor cleavage in other disease states

This technology is based on a previously unknown mechanism of action in insulin resistance. UCSD innovator, Dr. Geert Schmid-Schönbein, and his colleagues have discovered that certain inflammatory mediators cleave the insulin receptor on the cell surface. After being cleaved, the insulin receptor is no longer responsive and glucose uptake is significantly compromised. This is a newly discovered mechanism which has the potential of marginalizing current drugs on the market as none of them interfere with this mechanism.

In vivo testing in two animal species has confirmed the receptor cleavage and resultant reduced glucose uptake. Dr Schmid-Schönbein has also demonstrated that a drug which has been approved in the U.S. for over ten years successfully blocks the receptor cleavage and restores blood glucose and A1C levels to a normal range in severely diabetic rats.

A human study in 50 patients at the Veterans Affairs (VA) San Diego Hypertension Clinic has been completed which demonstrated similar results to the animal data and showed increased levels of matrix metallo-proteinase (MMPs) in diabetic/hypertensive patients. Several additional studies are ongoing at the VA San Diego Hypertension Clinic and at UCSD to further confirm elevated MMP and protease levels in diabetic and hypertensive patients. A recently completed human study in 36 patients at the VA San Diego confirmed that insulin receptor alpha levels are lower and MMP activity is higher in humans with obesity, inflammation, and DM2 (diabetes) compared to controls.

It is the intent of InhibeX to perform Phase II trials using either a currently approved medication or a new chemical entity to demonstrate safety and efficacy in the diabetes/metabolic space. Additional animal and human studies are planned in other disease states where receptor cleavage is suspected as a mechanism.


Insulin cells (shown in red)

InhibeX, LLC
A Leading BioSciences, Inc. Company
3580 Carmel Mountain Road Suite 300, San Diego, CA 92130
Tel: (858) 395-6099
Founded: 2006
Employees: 4

John Rodenrys – CEO
Hank Loy – President
Greg Doyle – CFO

Financing by Leading BioSciences, Inc.


Technology Innovator:


Geert Schmid-Schönbein,
PhD Professor, Bioengineering
Jacobs School of Engineering

  • Company Name: InhibeX, LLC
  • 3580 Carmel Mountain Road,